BofA lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $63 from $65 and keeps a Buy rating on the shares. FY25 guidance that was more conservative than consensus on topline and operating loss, notes the analyst, who thinks investors will “look beyond” the FY25 guide as the company’s larger commercial opportunities come into play post-2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $45 from $60 at BMO Capital
- Ionis Pharmaceuticals: Hold Rating Amid Revenue Growth, Competitive Pressures, and Delayed Catalysts
- Ionis Pharmaceuticals: Balancing Strong R&D Revenues with Market Challenges – Hold Rating Justified
- Ionis Pharmaceuticals price target lowered to $64 from $67 at Citi
- Ionis Pharmaceuticals Reports Strong 2024 Results